“The company has been informed by the U.S. Food and Drug Administration (US-FDA) that it will be lifting the Import Alert 66-40 and moving to close out the Warning letter issued to the company's Unit-II at Visakhapatnam,” Divi’s Laboratories said in a regulatory filing.
On September 20, 2017, the company said that all the previous observations by USFDA regarding Unit-2 of its Visakhapatnam facility have been confirmed as completed and resolved.
In past three months, the stock zoomed 60% as compared to 3% rise in the benchmark indices the S&P BSE Sensex and Nifty50.
At 09:20 AM; the stock was up 20% at Rs 1,105 on the BSE, as compared to 0.08% rise in the S&P BSE Sensex. The trading volumes on the counter jumped nearly four-fold with a combined 2.56 million shares changed hands in first five minutes of trade on the NSE and BSE.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in